SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Technology StocksInvesting in Exponential Growth


Previous 10 
From: Paul H. Christiansen3/7/2020 9:15:03 AM
   of 961
 
Google DeepMind’s effort on COVID-19 coronavirus rests on the shoulders of giants

There's been a quest for sixty years to understand the structure of proteins, ever since Nobel Prize winners Max Perutz and John Kendrew in the 1950s gave the world the first glimpse of what a protein looks like.

It was that pioneering work, and the decades of research that followed, that made possible the announcement on Thursday by Google's DeepMind that it has arrived at a guess as to the structure of a handful of proteins associated with the respiratory disease known as COVID-19 that is spreading around the world.

Proteins do the vast amount of the work of organisms, and understanding the three-dimensional shape of the proteins in COVID-19 could conceivably provide a kind of blueprint of the virus behind the disease, which could conceivably aid in coming up with a vaccine. Efforts are underway around the world to determine the structure of those viral proteins, of which DeepMind's is just one effort.

Read More – ZD Net

Share RecommendKeepReplyMark as Last Read


From: Paul H. Christiansen5/10/2020 11:26:47 AM
   of 961
 
The PlarityTE (PTE) Enigma

The Diabetic Foot Ulcer (DFU) Total Addressable Market (TAM) is projected to be $11 billion/year by 2026.

The Venus Leg Ulcer (VLU) TAM is projected to be $5 billion by 2026.

The burn TAM is projected to be $3 billion by 2026.

The TAM for these three treatments $19 billionper year.

Given the possibility that PTE’s SkinTE could become the Standard of Care for all three of these markets, let’s assume that PTE could achieve 15% annually of those markets.

That projects to $2.85 billion annual revenues.

PTE currently has a market cap of $34.9 million, with roughly 38.4 millions shares issued and outstanding.

If a larger pharmaceutical company was willing to buy PTE at a price equal to the projected revenues in 2026 ($2.85 billion) the acquisition cost would be roughly $74 per share.

The stock closed on Friday, May 8, 2020 at $0.91 per share.




Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Paul H. Christiansen who wrote (960)5/12/2020 1:03:47 PM
From: The Ox
   of 961
 
Any thoughts on this?

PolarityTE: $13.7 million in CEO compensation

PolarityTE is “a biotechnology company developing and commercializing regenerative tissue products and biomaterials.” As of March 31, the company had $39.5 million in cash on hand. In 2018, former CEO Denver Lough was paid $13,714,337 in total compensation, including a bonus of $1,010,000. Former CFO Paul Mann’s total compensation was even bigger, $13,862,967. The company also paid former COO Eric Swanson $4,525,587.

On April 12, the company received a $3.6 million forgivable loan from the Paycheck Protection Program.

The company announced that it would cut salaries for its current executives (and all at-will employees) by 10%. But this will have little impact on their total compensation, which is mostly conveyed through stock grants and options.

But on April 16, four days after the loan, the company awarded its current COO, Richard Hague, a $165,000 cash bonus and 115,000 stock units. The value of the cash bonus, not to mention the stock grant, was many times larger than Hague’s salary reduction. On the same day, Chief Counsel Cameron Hoyler received a $125,000 bonus and 100,000 stock units. The current CEO, David Seaburg, received 315,000 stock units.

Share RecommendKeepReplyMark as Last Read
Previous 10